Business Wire

Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Applications Research at the Shonan Research Center (T-CiRA)

Del

The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today the initiation of the joint research program to develop clinical applications of induced pluripotent stem cells. The "Takeda-CiRA Joint Program for iPS Cell Applications" (T-CiRA) will begin research in six core directions to explore clinical applications of stem cells in therapeutic areas including cancer, heart failure, diabetes mellitus, neuro-degenerative disorders and intractable muscle diseases.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151214005460/en/

Induced pluripotent stem (iPS) cell technologies have the potential to bring about ground-breaking transformations to future medical treatments, and their applications span a variety of fields, including drug discovery, cell therapy and drug safety assessments. During the next 10 years, Takeda will provide collaborative funding of 20 billion yen, and will jointly run multiple projects led by researchers invited from CiRA and other universities. The collaboration is expected to make significant contributions to the application of iPSC technology into clinical practice, which requires a significant amount of time, effort and investment. It is aligned with the purpose of National Projects of Japan on clinical applications of iPS cell technologies.

"I am so happy to see that the six research groups, comprised of researchers from Takeda and CiRA, have been kicked off their research projects, with generous support from Takeda. Using iPSC technology as a tool, this collaboration will develop new approaches to drug discovery and produce new cures to intractable diseases over the next 10 years," said Shinya Yamanaka, M.D., Ph.D., director of CiRA, who is a Nobel laureate in 2012 for his work on iPS cells.

"Takeda is proud to be part of this important research program. Academic and research partnerships, particularly with renowned scientific institutions such as Kyoto University, are critical to advancing clinical knowledge and potential future applications that could improve patient lives," said Christophe Weber, President & CEO of Takeda. "This partnership also marks a new direction for Takeda, by exploring cell therapies and genetic strategies to avert and remedy disease."

Currently, six projects, described below, are carried out simultaneously at Takeda's Shonan Research Center (Kanagawa, Japan) as the main venue, with approximately 60 researchers in total from CiRA and Takeda.

"New projects will be added to the T-CiRA Program when the new laboratory space is completed in April, 2016," said Seigo Izumo, who is Global Head of Regenerative Medicine and Takeda's chief advisor to Professor Yamanaka. "It is anticipated that the Program will have over 10 projects with participation of more than 100 researchers at its steady state."

 

Details of the six projects

Research leader   Theme
Makoto Ikeya

Associate Professor, CiRA

Research on neural crest cells:

Neural crest cells are vertebrate-specific cells that play a pivotal role in human development. Dr. Ikeya's team mainly focuses on neural crest stem cells for future drug discovery and regenerative medicine to treat disease in the wide variety of systems derived from these cells, such as kidney, gut and neurons.

Haruhisa Inoue

Professor, CiRA

ALS drug discovery and development using patient-derived iPSCs:

The aim of the project is to develop new drugs for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder, using patient derived iPSCs and Takeda’s compounds or drug libraries.

Shin Kaneko

Associate Professor, CiRA

Development of a novel immuno-cell therapy by iPSC-derived cancer antigen-specific cytotoxic T lymphocytes:

Dr. Kaneko's team is developing new cancer immuno-cell therapy drugs using iPSC technology. In addition, the combination of the iPS cell stock at CiRA and Takeda’s experience in drug development allows the team to investigate advanced regenerative medicine for cancer treatment.

Kenji Osafune

Professor, CiRA

iPS cell technology-based regenerative therapy for type 1 diabetes and drug discovery for type 2 diabetes:

Dr. Osafune’s team seeks to develop cell therapy against type 1 diabetes, by transplanting iPSC-derived pancreatic cells. In addition, drug discovery against type 2 diabetes, will be performed using iPSC-derived pancreatic cells and Takeda’s chemical compound libraries.

Hidetoshi Sakurai

Associate Professor, CiRA

Drug discovery for intractable muscular disease by patient-derived iPSCs:

Dr. Sakurai's team aims to establish new drugs for treating muscular diseases, such as muscular dystrophy or myopathy. To achieve this goal, they will utilize patient-derived iPSCs as a tool for disease modeling and drug screening.

Yoshinori Yoshida

Junior Associate Professor, CiRA

  Drug discovery for cardiac disease using next generation platforms:

Dr. Yoshida's research team aims to develop next generation platforms for drug discovery using iPSC-derived heart muscle cells by taking advantage of new technologies developed at CiRA, such as "micro RNA-switch". The team will develop a way to obtain stage- and subtype-specific heart muscle cells from human iPSCs, which facilitates disease modeling and drug discovery. The eventual goal is to discover new drugs for treatment of heart failure using such platforms.

 

About the Center for iPS Cell Research and Application at Kyoto University (CiRA)
CiRA was established on April 1, 2010 to serve as the world’s first core institute dedicated to pioneering iPS cell research. With Dr. Shinya Yamanaka serving as Director, CiRA’s 30 research groups are engaged in fundamental science of cell reprogramming and human development, clinical applications, and bioethics, with the overall goal of using iPS cells to realize regenerative medicine and drug discovery. Additional information about CiRA is available through its website at www.cira.kyoto-u.ac.jp

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Related materials
Press release: CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research
http://www.takeda.com/news/2015/20150417_6964.html
T-CiRA website
http://www.takeda.com/t-cira/

Contact information

Media contacts
Center for iPS Cell Research and Application at Kyoto University (CiRA)
Akemi Nakamura and Hiroyuki Wadahama, +81 (0)75-366-7005
International Public Communications Office
media@cira.kyoto-u.ac.jp
or
Takeda Pharmaceutical Company Ltd.
Japanese Media
Tsuyoshi Tada, +81 (0)3-3278-2417
tsuyoshi.tada@takeda.com
or
Media outside Japan
Jocelyn Gerst, +1 (224) 554-5542
jocelyn.gerst@takeda.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Enters into a Memorandum of Understanding with Al-Farabi Kazakh National University22.7.2018 09:52Pressemelding

The American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, and the Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan, signed a Memorandum of Understanding (MoU), agreeing to exchange students, faculty, and research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180722005025/en/ The Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan and the American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, exchange a gift to commemorate their universities uniting in an MoU agreement. (Photo: AETOSWire) In the spirit of fostering a close international relationship between the Republic of Kazakhstan and the United Arab Emirates, developing bilateral relations in educational and scientific fields, and wishing to make their own contributions to the

Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.21.7.2018 18:19Pressemelding

The board of directors of Philip Morris International (NYSE:PM) has its board member, Sergio Marchionne, and his family in our thoughts and prayers during this challenging time. We congratulate our board chairman, Louis Camilleri, as he assumes the role of CEO of Ferrari S.p.A. The long term relationship between our two companies is deep and meaningful and we look forward to continued business collaboration. Mr. Camilleri will continue to serve as non-executive chairman of the PMI board. Philip Morris International: Who We Are We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirem

Loxam Announces a Conditional Agreement to Acquire UK Platforms20.7.2018 14:51Pressemelding

Loxam Group (“Loxam”) announces that its wholly-owned subsidiary Nationwide Platforms Limited (“Nationwide”) has entered into a conditional agreement with HSS Hire Group plc (“HSS”) with respect to the acquisition of UK Platforms Limited (“UKP”). UKP specializes in renting powered access equipment from its 12 branches located throughout the United Kingdom. The company has approximately 130 employees and operates a fleet of 3,000 units. UKP is controlled by HSS since 2013. As part of this transaction, Nationwide has entered into a commercial agreement with HSS to provide powered access equipment to complement HSS’ existing fleet. The closing of the transaction is subject to the approval by HSS’ shareholders and the confirmation that it will not be referred to the Competition and Mergers Authority. The transaction is expected to close before year end 2018. Don Kenny, CEO of Loxam’s Powered Access Division states: “I am delighted with the acquisition of UKP which will further reinforce NW

Schlumberger Announces Second-Quarter 2018 Results20.7.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2018 Mar. 31, 2018 Jun. 30, 2017 Sequential Year-on-year Revenue $8,303 $7,829 $7,462 6% 11% Pretax operating income $1,094 $974 $950 12% 15% Pretax operating margin 13.2% 12.4% 12.7% 75 bps 45 bps Net income - GAAP basis $430 $525 $(74) -18% n/m Net income, excluding charges & credits* $594 $525 $488 13% 22% Diluted EPS - GAAP basis $0.31 $0.38 $(0.05) -18% n/m Diluted EPS, excluding charges & credits* $0.43 $0.38 $0.35 13% 23% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “The second quarter was both busy and exciting for Schlumberger as we completed a number of major milestones in preparation for the broad-based global activity upturn that is now emerging. We delivered solid top-line gro

H.I.G. Capital Announces the Sale of KidsFoundation19.7.2018 19:50Pressemelding

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €21 billion of equity capital under management, announced today that one of its affiliates has entered a definitive agreement to sell the KidsFoundation Group (“KidsFoundation”), the Dutch market leader in childcare services, to Onex Corporation (“Onex”)(TSX:ONEX). Terms were not disclosed. Headquartered in Almere, the Netherlands, KidsFoundation provides high-quality childcare to nearly 30,000 children between the ages of six weeks and 12 years. H.I.G. created KidsFoundation in 2014 through the acquisition of assets from the estate of Estro Group. During H.I.G.’s ownership, the company has developed strongly with significant capital invested by H.I.G. to create a high-quality childcare offering. H.I.G. worked with KidsFoundation management to optimise the footprint of the company by exiting loss-making locations, introduce new IT systems to drive operational improvement and develop an internal M&

SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results19.7.2018 16:01Pressemelding

We are pleased to announce our quarterly conference call to discuss the results of SIG Combibloc Group Holdings S.à r.l. for the second quarter ended June 30, 2018. Date: Monday, July 23, 2018 Time: 15.00 CEST / 14.00 BST / 9.00 EDT The call information will be distributed on our secure site. If you would like access to our call, please contact investor.relations@sig.biz . Regards, SIG Combibloc Group Holdings S.à r.l. View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005634/en/ Contact information SIG Combibloc Group Holdings S.à r.l. Jennifer Gough investor.relations@sig.biz